Prevention and Detection of Prostate Cancer cells
The prostate gland is part of the male reproductive system. It produces most of the fluid that makes up the semen that enriches sperm. The male hormone testosterone is required to grow and develop the prostate. Sometimes this can cause problems, such as difficulty urinating. These problems are common in older men and not always symptoms or signs of cancer. Prostate cancer that's detected early when it's still restricted to the prostate gland, has a better chance of successful treatment.
The symptoms are Feeling the frequent or sudden need to urinate, finding it difficult to urinate, for example, trouble starting or not being able to urinate when the feeling is there or poor urine flow, discomfort when urinating, finding blood in urine or semen and pain in the lower back, upper thighs or hips.
Risk factor contributing towards Prostate Cancer are age and family history i.e. “Prostate cancer is an age-dependent disease.” The risk of getting prostate cancer from the age range of 75 to 85 is 1 in 7 and 5 men respectively. The chances of you developing prostate cancer are related to the male relative or to the senior male relative in your family diagnosed with the same.
Treatment for Prostate Cancer:
The Prostate Specific Antigen (PSA) blood test result shows whether there is an increase in this specific protein. Depending on the result, you may need to further investigate by a specialist. A high PSA test result does not necessarily mean cancer. If your tests show you increase in PSA, then you may be at risk. The next step is biopsy which is the only way a firm diagnosis of prostate cancer can be made. A urologist removes small samples of tissue from your prostate, using very thin, hollow needles guided by an ultrasound. The perineum transperineal, the tissue is sent to a pathologist to identify whether the cells are malignant cancerous or benign.
RNA polymerase and template DNA that encodes the antigen(s) of interest, as we administer and internalize by host cells mRNA transcripts are then translated directly into the cytoplasm which results in antigens being present in the antigen presenting cells to stimulate an immune response. Alternatively, dendritic cells can be loaded with either tumor-associated antigen mRNA or total tumor RNA and delivered to the host to elicit a specific immune response.